PA-PMI
Project Management Institute (PMI) today announced that its Board of Directors has named Pierre Le Manh as President and Chief Executive Officer (CEO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005706/en/
Starting September 1, Pierre Le Manh, a veteran CEO of professional services and knowledge industries, will lead PMI’s fast-growing global organization and oversee the continued execution of PMI’s Impact Strategy. In his role, Pierre will also serve as the lead advocate for PMI’s global organization and close to a hundred million project professionals worldwide.
“We are very excited to bring Pierre Le Manh on board after a thorough selection process,” said Jennifer Tharp, PMP, Chair of PMI’s Board of Directors. “We have big ambitions for the future of our profession and the Project Management Institute as a leading global organization. Pierre brings the global experience and credentials to accelerate PMI’s current business and further our innovation and transformation journey. As Michael DePrisco will resume his responsibilities as PMI’s chief operating officer, the Board and myself want to express our gratitude to Michael for serving as interim CEO during the selection process.”
Pierre Le Manh has served in CEO roles for over 20 years at knowledge, research, and technology-based companies worldwide. He has lived and worked in Paris, Montreal, London, Rome, and New York City. He brings a proven track record of growth, transformation, and globalization and a passion for team building and nurturing culture.
“Think about what project professionals have achieved across all sectors of the economy and society: from construction to technology, from healthcare to government, from consumer goods to infrastructure, from arts to sciences,” said Le Manh. “Maybe even more importantly, think of the daunting tasks ahead of them when humanity has no other choice than to pursue more sustainable development in the future. Without competent professionals to lead and run projects, ideas cannot be made a reality. Project professionals are the doers and builders of transformation.”
“I am eager to work with PMI’s Board, Michael DePrisco and the leadership team, and our growing global team of more than 700 permanent employees to take on the challenges of a new era, innovate and build upon PMI’s status as a fast-growing global leader in professional development, education, and upskilling,” continued Le Manh. “I enthusiastically look forward to meeting and working with the greater global mission-driven community of changemakers of more than 300 chapters, 10,000 volunteers, and close to 700,000 active PMI members to create better outcomes for individuals, businesses, and society worldwide.”
Before joining PMI, Pierre Le Manh recently led a project for the North American expansion of Galileo Global Education, a European leader in post-secondary higher education and education technology. Until 2021, he served as the Chief Executive Officer of North America and Global Deputy CEO of Ipsos, the global leader in market research and data analytics, where he played a key leadership role in the company’s global expansion for over 15 years, first as CEO for EMEA and then as global head of several professional practices before heading the North American business. Before Ipsos, he held several other CEO positions in technology-based services and publishing.
“I am very excited to leverage the broad and deep experience I have gained over my career to lead the PMI organization and, in particular, to create a stronger membership experience for project professionals seeking lifelong learning and development opportunities and for corporate partners investing in reskilling and upskilling their workforce,” Le Manh said.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the leading professional development organization for project management and the authority for a growing global community of millions of professionals of the project economy who use project, program, and portfolio management skills and competencies.
Building on a proud legacy dating to 1969, PMI is a not-for-profit for-purpose organization working in nearly every country to advance careers, strengthen organizational success, and enable project professionals and changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
PMI empowers people to make ideas a reality and helps professionals and changemakers create better outcomes for businesses, communities, and society worldwide. Through global advocacy, networking, collaboration, research, and education, PMI prepares organizations and individuals at every stage of their career journey to work smarter to drive success in a world of change.
Visit us at www.PMI.org , LinkedIn , https://www.facebook.com/PMInstitute , and on Twitter @PMInstitute .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005706/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom